testicular disease: A non-neoplastic or neoplastic disorder affecting the testis. Representative examples include torsion, infarction, germ cell tumor, sex cord-stromal tumor, lymphoma, and leukemia.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleonly males |
226754 |
2. Check conditionsNone |
226754 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
164 |
4. Check minimum number of eventsNone |
164 |
5. Include endpointsNone |
164 |
6. Filter based on genotype QC (FinnGen only) |
159 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Testicular dysfunction, other/unspecified
based on the number of shared cases.
Similar with more cases:
- Testicular dysfunction
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1111 | - | 1111 |
| Only index persons | 1058 | - | 1058 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | - | 0.03 |
| Only index persons | 0.04 | - | 0.04 |
| Median age at first event (years) | |||
| Whole population | - | - | 39.11 |
| Only index persons | - | - | 39.11 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 159 | - | 159 |
| Unadjusted period prevalence (%) | 0.07 | - | 0.07 |
| Median age at first event (years) | 51.37 | - | 51.37 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 164
- Matched controls
- 1640
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
46.5
139.9
102
56
E29.9
ICD-10 Finland
Testicular dysfunction, unspecified
1716.9
130.8
110
*
E29.8
ICD-10 Finland
Other testicular dysfunction
+∞
60.2
54
*
E23.04
ICD-10 Finland
Hypogonadotropic hypogonadism
38.5
27.2
34
11
E29.1
ICD-10 Finland
Testicular hypofunction
24.9
24.2
34
17
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
18.0
17
*
A55
ICPC
General and Unspecified, Local injection/infiltration
66.9
16.1
18
*
KF8AE
NOMESCO Finland
Ultrasound examination of scrotum
6.7
14.0
24
41
121
Kela drug reimbursment
Severe hypofunction of sexual glands
140.3
12.6
13
*
A50
ICPC
General and Unspecified, Medication/prescr/renewal
10.2
10.4
20
22
Y28
ICPC
Limited function/disability (Y)
42.9
10.1
12
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
+∞
8.4
8
*
G47.3
ICD-10 Finland
Sleep apnoea
2.6
7.9
64
322
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.8
7.0
23
68
-50
ICPC
Medication/prescr/renewal
8.9
7.0
14
17
N03AX16
ATC
[U] pregabalin
2.7
6.9
45
201
N02AX02
ATC
tramadol; systemic, rectal
2.4
6.8
82
487
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
8.4
6.8
14
18
G03GA01
ATC
chorionic gonadotrophin; parenteral
72.6
6.5
7
*
R53
ICD-10 Finland
Malaise and fatigue
2.6
6.0
41
186
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
50
51
13.67
46.05
2.3
1.5
5.96
4.40
u/l
1.02
42
41
21
35
6.73
12.47
2.5
1.3
171.40
189.17
pmol/l
0.26
21
35
125
774
3.59
11.61
4.2
4.0
1.39
1.66
ug/l
1.11
119
701
123
817
3.02
8.90
3.6
2.9
14.74
14.79
pmol/l
0.08
117
741
145
1063
4.14
8.81
4.3
3.6
1.84
1.96
mu/l
0.68
135
978
102
620
2.71
8.69
4.0
3.7
27.31
20.50
%
1.93
36
244
80
446
2.55
7.94
2.8
2.6
0.67
0.68
ug/l
0.04
41
246
31
116
3.06
6.54
8.5
8.7
—
—
—
0
0
24
79
3.39
6.22
7.3
2.3
63.11
66.43
ml/min/173m2
—
9
35
69
410
2.18
5.43
3.3
2.8
—
—
—
0
0
71
440
2.08
4.91
3.0
3.1
—
—
—
0
0
84
554
2.06
4.90
3.8
4.2
0.00
0.00
estimate
-0.00
18
94
84
562
2.01
4.63
3.0
3.0
0.00
0.00
estimate
-0.00
16
87
100
716
2.02
4.51
5.3
6.2
6.52
6.93
mmol/l
1.04
94
686
83
557
1.99
4.50
3.0
3.0
0.00
0.01
estimate
0.50
17
100
122
945
2.14
4.35
8.3
8.5
77.10
76.53
u/l
0.04
115
908
77
510
1.96
4.28
5.4
8.8
1.21
1.20
mmol/l
0.56
68
440
70
454
1.95
4.10
5.3
3.4
21.86
36.76
ng/l
1.11
49
293
40
212
2.17
4.05
2.2
2.1
2.93
3.17
mg/l
0.27
35
185
49
289
1.99
3.72
3.6
3.2
0.00
0.01
estimate
0.49
18
89
150
1299
2.81
3.60
17.6
12.7
26.66
23.82
mg/l
0.43
120
1022
44
258
1.96
3.36
1.8
1.7
0.93
1.63
mg/l
0.97
36
196
50
308
1.90
3.30
3.8
2.6
0.43
0.48
e6/l
0.05
38
227
53
334
1.87
3.26
2.7
2.5
394.13
8185.96
umol/l
1.55
47
294
56
360
1.84
3.23
3.4
4.1
3.94
8.76
mg/mmol
1.61
41
254
142
1219
2.23
3.14
14.9
11.3
84.33
89.00
ml/min/173m2
1.58
124
1026
28
143
2.16
3.08
2.5
2.0
—
—
—
0
0
68
471
1.76
3.03
4.4
7.8
1.21
1.20
mmol/l
0.23
60
435
40
235
1.93
3.02
1.6
1.5
—
—
—
0
0
8
17
4.89
2.96
1.1
1.1
—
—
—
0
0
93
708
1.72
2.93
8.8
10.5
4.08
4.20
e9/l
0.17
84
631
68
483
1.70
2.71
2.3
2.8
—
—
—
0
0
30
166
1.99
2.68
2.4
1.7
—
—
—
0
0
24
123
2.11
2.62
2.8
4.7
215.63
243.22
u/l
0.77
24
117
29
162
1.96
2.52
2.7
2.1
—
—
—
0
0
105
849
1.66
2.45
3.9
3.7
8.74
9.20
mm/h
0.11
97
804
37
229
1.80
2.35
3.9
3.7
5483.36
326.29
ng/l
0.46
28
180
41
262
1.75
2.34
1.3
1.3
0.75
0.85
u/ml
0.44
13
77
54
382
1.62
2.10
1.9
1.8
93.10
94.64
pmol/l
0.08
33
214
15
70
2.26
2.05
2.3
1.2
—
—
—
0
0
139
1237
1.81
2.01
4.4
4.2
6.13
6.04
mmol/l
0.37
126
1155
112
948
1.57
1.93
3.2
3.1
—
—
—
0
0
25
147
1.83
1.87
1.8
1.9
—
—
—
0
0
149
1364
2.01
1.83
5.6
4.6
2.72
2.85
mmol/l
1.00
142
1288
31
196
1.72
1.83
2.9
2.5
0.24
0.99
e6/l
2.08
14
112
29
181
1.73
1.79
2.8
2.6
0.32
0.33
e6/l
0.01
13
96
33
214
1.68
1.78
1.8
1.4
16.50
19.69
nmol/l
0.86
28
194
45
320
1.56
1.68
4.4
3.2
2.35
2.34
mmol/l
0.18
39
287
43
309
1.53
1.52
3.1
3.1
1060.46
721.49
ng/l
0.41
36
252
37
257
1.57
1.52
1.9
2.5
—
—
—
0
0
23
142
1.72
1.48
1.7
1.8
—
—
—
0
0
13
67
2.02
1.43
1.4
1.2
284.98
340.51
u/ml
0.08
13
59
32
220
1.56
1.37
1.6
1.7
432.50
422.74
pmol/l
0.07
26
189
69
555
1.42
1.37
9.9
12.6
1.06
1.26
inr
4.61
26
163
5
17
3.00
1.37
5.4
5.1
—
—
—
0
0
6
24
2.56
1.31
1.3
1.3
—
—
—
0
0
24
157
1.62
1.26
6.5
9.4
104.79
104.03
mmol/l
0.42
24
157
6
25
2.45
1.25
1.2
1.3
—
—
—
0
0
145
1349
1.65
1.23
5.2
4.2
1.21
1.28
mmol/l
1.68
137
1273
21
134
1.65
1.21
3.9
4.0
26.85
28.37
%
0.26
13
98
18
112
1.68
1.14
4.4
10.6
1.29
1.46
mmol/l
0.45
18
112
28
196
1.52
1.12
1.9
2.0
—
—
—
0
0
5
22
2.31
1.04
1.4
1.1
—
—
—
0
0
144
1349
1.55
1.04
5.2
4.2
4.45
4.62
mmol/l
1.13
137
1284
24
166
1.52
1.01
1.2
1.2
9.88
20.54
iu/ml
—
8
46
60
493
1.34
0.99
5.0
5.8
36.65
36.96
g/l
0.15
55
472
5
23
2.21
0.98
1.6
1.4
—
—
—
0
0
117
1062
1.35
0.96
3.7
3.5
54.65
54.02
u/l
0.03
110
1010
8
43
1.90
0.89
2.0
2.8
—
—
—
0
0
6
30
2.04
0.88
1.0
2.5
—
—
—
0
0
0
24
0.00
0.80
0.0
1.1
—
—
—
0
0
6
34
1.79
0.77
1.3
1.6
—
—
—
0
0
7
39
1.83
0.73
2.0
2.8
—
—
—
0
0
139
1317
1.36
0.69
5.0
3.8
1.42
1.42
mmol/l
0.04
130
1246
5
27
1.88
0.69
1.6
1.6
—
—
—
0
0
27
330
0.78
0.51
1.5
1.8
1.70
1.54
mmol/l
0.33
22
282
5
31
1.63
0.43
1.0
1.1
—
—
—
0
0
5
31
1.63
0.43
1.6
1.1
—
—
—
0
0
5
32
1.58
0.42
1.6
1.1
—
—
—
0
0
8
58
1.40
0.42
1.1
1.0
—
—
—
0
0
5
33
1.53
0.41
1.8
1.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
8
60
1.35
0.41
1.5
1.3
—
—
—
0
0
5
35
1.44
0.39
1.4
1.3
—
—
—
0
0
0
19
0.00
0.39
0.0
10.7
—
50.78
—
0
9
18
144
1.28
0.37
1.2
1.2
1.09
6.58
u/ml
1.12
12
61
11
84
1.33
0.31
2.7
1.5
—
—
—
0
0
5
38
1.33
0.23
1.2
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.1
—
—
—
0
0
7
62
1.13
0.17
1.1
1.3
—
—
—
0
0
8
68
1.19
0.17
2.3
1.6
—
—
—
0
0
10
83
1.22
0.16
14.0
14.0
26.28
24.32
mmol/l
—
10
77
14
122
1.16
0.14
7.5
15.9
136.93
125.90
g/l
1.05
14
117
10
85
1.19
0.12
1.7
1.7
—
—
—
0
0
18
164
1.11
0.10
2.1
1.6
1053.20
1254.95
nmol/l
0.34
11
130
6
53
1.14
0.09
2.8
3.0
—
—
—
0
0
12
121
0.99
0.00
6.0
2.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.1
—
121.64
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
1088.57
—
0
7
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.9
—
14.13
—
0
8
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
5
0.00
-0.00
0.0
1.4
—
137.20
—
0
5
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.7
—
1000.67
—
0
9
0
8
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
11.91
—
0
9
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.7
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_TESTICDYSNAS and mortality.
Females
No dataMales
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_TESTICDYSNAS | 1.564 [1.05, 2.32] | 0.026 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 52 out of 694 males with E4_TESTICDYSNAS died.
Mortality risk
Mortality risk for people of age
years, who have E4_TESTICDYSNAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | 0.294% |
| 5 | No data | 1.847% |
| 10 | No data | 4.324% |
| 15 | No data | 8.11% |
| 20 | No data | 13.644% |
Relationships between endpoints
↥Index endpoint: E4_TESTICDYSNAS – Testicular dysfunction, other/unspecified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data